{"id":"fc1b21d61ae0","type":"article","url":"https://hartvaat.nl/2026/05/18/naar-precisiecardiologie-na-het-hartinfarct-opkomende-biomarkers-voor-risicostra/","title":"Naar precisiecardiologie na het hartinfarct: opkomende biomarkers voor risicostratificatie","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["abelacimab","acuut-hartfalen","biomarkers-cardiovasculair","inflammatie","laminopathie","lipoproteïne-a","menopauze","myocardinfarct","nt-probnp","troponine","vrouwen"],"journal":"European heart journal. Quality of care & clinical outcomes","doi":"10.1093/ehjqcco/qcag086","source_url":"https://doi.org/10.1093/ehjqcco/qcag086","authors":["Simón Rodríguez-Moar","Carmen Neiro-Rey","David García-Molinero","José M García-Acuña","Pedro Rigueiro-Veloso","Diego Iglesias-Álvarez","Brais Díaz-Fernández","Miguel Souto-Bayarri","José R González-Juanatey","Ezequiel Álvarez","Rosa M Agra-Bermejo"],"significance":6,"published":"2026-06-18","source_date":"2026-05-18","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/","https://hartvaat.nl/kennis/lipiden/genetisch-onderzoek-fh/"],"congress":"","summary_en":"EHJ Quality of Care review of biomarkers for prognosis after myocardial infarction (MI). Despite significant advances in acute MI care, long-term prediction and risk stratification remain challenging. Cardiac troponins and natriuretic peptides remain standard for diagnosis and initial risk evaluation. Emerging biomarkers — galectin-3, lipoprotein(a), receptor for advanced glycation end-products (RAGE), and non-coding RNAs — are associated with higher mortality and major adverse cardiovascular events. Further exploration of their biological roles may yield new therapeutic targets. Combined with omics, imaging modalities, and digital monitoring, refined phenotypic characterisation enables personalised post-MI management.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T18:39:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Overzichtsartikel in EHJ Quality of Care over biomarkers voor prognose na myocardinfarct (MI). Ondanks aanzienlijke vooruitgang in acute MI-zorg blijven langetermijnvoorspelling en risicostratificatie een uitdaging. Cardiale troponines en natriuretische peptiden blijven standaard voor diagnostiek en initiële risicobeoordeling. Nieuwere biomarkers — galectine-3, lipoproteïne(a), receptor for advanced glycation end products (RAGE) en non-coding RNAs — zijn geassocieerd met hogere sterfte en major adverse cardiovascular events. Voortgaande verkenning van hun biologische rollen kan nieuwe therapeutische aangrijpingspunten opleveren. Combinatie met omics, beeldvorming en digitale monitoring maakt verfijndere fenotypering mogelijk, en daarmee gepersonaliseerde management-strategieën na MI.","abstract_original":"Cardiovascular diseases remain the leading cause of mortality worldwide, underscoring the urgent need for improved strategies to reduce their global burden. Despite significant advances in the acute management of myocardial infarction (MI) -notably in reducing short-term mortality and extending patient survival- key gaps persist in our understanding of post-infarction pathophysiology and risk stratification. In particular, predicting long-term outcomes and adverse cardiovascular events following MI continues to be a major clinical challenge. This review provides an overview of emerging biomarkers supported by current scientific evidence that show promise in enhancing prognostic assessment after MI. While cardiac troponins and natriuretic peptides remain the standard for diagnosis and initial risk evaluation, novel biomarkers such as galectin-3, lipoprotein(a), receptor for advanced glycation end-products and non-coding RNAs have been associated with increased risk of mortality and major adverse cardiovascular events. A deeper exploration of their biological roles and related signalling pathways may contribute to the identification of new therapeutic targets. In parallel, recent advances in omics technologies, imaging modalities and digital monitoring are enabling more refined phenotypic characterization of post-MI patients, paving the way for personalized management strategies. Altogether, these developments offer a path toward improved prognostication, targeted therapies, and ultimately better clinical outcomes for individuals recovering from MI."}